Previous issues

Volume 31(1) Jan 2025
Print ISSN: 2287-2728
Online ISSN: 2287-285X

Reviews Roles of X-box binding protein 1 in liver pathogenesis

Jihoon Tak, Yun Seok Kim, Sang Geon Kim

Clin Mol Hepatol. 2025;31(1):1-31.

Sinusoidal communication in chronic liver disease

Albert Gibert-Ramos, María Andrés-Rozas, Raül Pastó, Pablo Alfaro-Retamero, Sergi Guixé-Muntet, Jordi Gracia-Sancho

Clin Mol Hepatol. 2025;31(1):32-55.

Bioactive metabolites: A clue to the link between MASLD and CKD?

Wen-Ying Chen, Jia-Hui Zhang, Li-Li Chen, Christopher D. Byrne, Giovanni Targher, Liang Luo, Yan Ni, Ming-Hua Zheng, Dan-Qin Sun

Clin Mol Hepatol. 2025;31(1):56-73.

Long-term outcomes and risk modifiers of metabolic dysfunction-associated steatotic liver disease between lean and non-lean populations

Pojsakorn Danpanichkul, Kanokphong Suparan, Vitchapong Prasitsumrit, Aijaz Ahmed, Karn Wijarnpreecha, Donghee Kim

Clin Mol Hepatol. 2025;31(1):74-89.

Hard-to-treat autoimmune hepatitis and primary biliary cholangitis: The dawn of a new era of pharmacological treatment

Atsumasa Komori, Yuki Kugiyama

Clin Mol Hepatol. 2025;31(1):90-104.

Original Articles Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)

Chuan Liu, Hong You, Qing-Lei Zeng, Yu Jun Wong, Bingqiong Wang, Ivica Grgurevic, Chenghai Liu, Hyung Joon Yim, Wei Gou, Bingtian Dong, Shenghong Ju, Yanan Guo, Qian Yu, Masashi Hirooka, Hirayuki Enomoto, Amr Shaaban Hanafy, Zhujun Cao, Xiemin Dong, Jing LV, Tae Hyung Kim, Yohei Koizumi, Yoichi Hiasa, Takashi Nishimura, Hiroko Iijima, Chuanjun Xu, Erhei Dai, Xiaoling Lan, Changxiang Lai, Shirong Liu, Fang Wang, Ying Guo, Jiaojian Lv, Liting Zhang, Yuqing Wang, Qing Xie, Chuxiao Shao, Zhensheng Liu, Federico Ravaioli, Antonio Colecchia, Jie Li, Gao-Jun Teng, Xiaolong Qi

Clin Mol Hepatol. 2025;31(1):105-118.

Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial

Woo Hyun Paik, Joo Kyung Park, Moon Jae Chung, Gunn Huh, Ce Hwan Park, Sang Hyub Lee, Heon Se Jeong, Hee Jin Kim, Do Hyun Park

Clin Mol Hepatol. 2025;31(1):119-130.

Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation

Soon Kyu Lee, Ho Joong Choi, Young Kyoung You, Pil Soo Sung, Seung Kew Yoon, Jeong Won Jang, Jong Young Choi

Clin Mol Hepatol. 2025;31(1):131-146.

USP29 alleviates the progression of MASLD by stabilizing ACSL5 through K48 deubiquitination

Sha Hu, Zhouxiang Wang, Kun Zhu, Hongjie Shi, Fang Qin, Tuo Zhang, Song tian, Yanxiao Ji, Jianqing Zhang, Juanjuan Qin, Zhigang She, Xiaojing Zhang, Peng Zhang, Hongliang Li

Clin Mol Hepatol. 2025;31(1):147-165.

Self-testing strategy to eliminate hepatitis C as per World Health Organization’s goal: Analysis of disease burden and cost-effectiveness

Gyeongseon Shin, Beom Kyung Kim, SeungJin Bae, Hankil Lee, Sang Hoon Ahn

Clin Mol Hepatol. 2025;31(1):166-178.

Metabolic dysfunction-associated steatotic liver disease exhibits sex-specific microbial heterogeneity within intestinal compartments

Carlos Jose Pirola, Maria Silvina Landa, Mariano Schuman, Silvia Inés García, Adrian Salatino, Silvia Sookoian

Clin Mol Hepatol. 2025;31(1):179-195.

Aberrant fragmentomic features of circulating cell-free mitochondrial DNA enable early detection and prognosis prediction of hepatocellular carcinoma

Yang Liu, Fan Peng, Siyuan Wang, Huanmin Jiao, Kaixiang Zhou, Wenjie Guo, Shanshan Guo, Miao Dang, Huanqin Zhang, Weizheng Zhou, Xu Guo, Jinliang Xing

Clin Mol Hepatol. 2025;31(1):196-212.

Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial

Yao-Chun Hsu, Chi-Yi Chen, Cheng-Hao Tseng, Chieh-Chang Chen, Teng-Yu Lee, Ming-Jong Bair, Jyh-Jou Chen, Yen-Tsung Huang, I-Wei Chang, Chi-Yang Chang, Chun-Ying Wu, Ming-Shiang Wu, Lein-Ray Mo, Jaw-Town Lin

Clin Mol Hepatol. 2025;31(1):213-226.

Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis

Nicholas A. Rouillard, Scott D. Barnett, Xinrong Zhang, Leslie Kam, Richie Manikat, Ramsey Cheung, Mindie H. Nguyen

Clin Mol Hepatol. 2025;31(1):227-239.

Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis

Anja Tiede, Lena Stockhoff, Zhaoli Liu, Hannah Rieland, Jim B. Mauz, Valerie Ohlendorf, Birgit Bremer, Jennifer Witt, Anke Kraft, Markus Cornberg, Jan B. Hinrichs, Bernhard C. Meyer, Heiner Wedemeyer, Cheng-Jian Xu, Christine S. Falk, Benjamin Maasoumy

Clin Mol Hepatol. 2025;31(1):240-255.

Editorials Spotting undiagnosed significant liver fibrosis in the general population: impact on subsequent clinical care: Editorial on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis”

Nana Peng, Mary Yue Wang, Sherlot Juan Song, Terry Cheuk-Fung Yip

Clin Mol Hepatol. 2025;31(1):256-260.

Hepatocellular carcinoma surveillance after sustained virological response in chronic hepatitis C: Editorial on “Non-invasive prediction of post-sustained virological response hepatocellular carcinoma in hepatitis C virus: A systematic review and meta-analysis”

Ho Soo Chun, Minjong Lee

Clin Mol Hepatol. 2025;31(1):261-263.

Towards unification of liver stiffness measurement cutoffs: Editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis”

Yangyue Zhang, Vincent Wai-Sun Wong

Clin Mol Hepatol. 2025;31(1):264-267.

The use of transient elastography for predicting hepatocellular carcinoma in chronic hepatitis B patients: Editorial on “Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis”

Mirko Zoncapè, Emmanuel A. Tsochatzis

Clin Mol Hepatol. 2025;31(1):268-274.

Transient elastography for assessing liver fibrosis in autoimmune liver diseases: Excellent performance but limited details: Editorial on “Diagnostic accuracy of vibration-controlled transient elastography for staging liver fibrosis in autoimmune liver diseases: A systematic review and meta-analysis”

Kyung-Ah Kim

Clin Mol Hepatol. 2025;31(1):275-276.

Essential tools for assessing advanced fibrosis in metabolic dysfunction-associated steatotic liver disease: Editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis”

Won Sohn

Clin Mol Hepatol. 2025;31(1):277-280.

UBE2S: A novel driver of HIF-1alpha-induced metabolic reprogramming in hepatocellular carcinoma: Editorial on “UBE2S promotes glycolysis in hepatocellular carcinoma by enhancing E3 enzyme-independent polyubiquitination of VHL”

Martina Mang Leng Lei, Terence Kin Wah Lee

Clin Mol Hepatol. 2025;31(1):281-285.

From past to pandemic: Health disparities in US hepatobiliary cancer mortality before and during COVID-19: Editorial on “Burden of mortality from hepatocellular carcinoma and biliary tract cancers by race and ethnicity and sex in US, 2018–2023”

Ilona Argirion

Clin Mol Hepatol. 2025;31(1):286-289.

MASLD after hepatitis C virus eradication: Do not overlook the cardiometabolic risk factors: Editorial on “Dynamic change of metabolic dysfunction-associated steatotic liver disease in chronic hepatitis C patients after viral eradication: A nationwide registry study in Taiwan”

Rex Wan-Hin Hui, Lung-Yi Mak

Clin Mol Hepatol. 2025;31(1):290-292.

TM6SF2 and PNPLA3: A potential dynamic duo?: Editorial on “TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD”

Andrea Caddeo, Rosellina M. Mancina

Clin Mol Hepatol. 2025;31(1):293-296.

A complement to epigenetics in metabolic dysfunction-associated steatotic liver disease: Editorial on “DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dysfunction-associated steatotic liver disease”

Johanna K. DiStefano, Glenn S. Gerhard

Clin Mol Hepatol. 2025;31(1):297-300.

Unveiling the distinctive gut microbiota and metabolites in liver cirrhosis and its complications: Novel diagnostic biomarkers: Editorial on “Gut microbiome and metabolome signatures in liver cirrhosis-related complications”

Soon Kyu Lee, Jong Young Choi

Clin Mol Hepatol. 2025;31(1):301-303.

Identification of KCTD17 as a Ras stabilizer in hepatocellular carcinoma: Editorial on “KCTD17-mediated Ras stabilization promotes hepatocellular carcinoma progression”

Rainbow Wing Hei Leung, Terence Kin Wah Lee

Clin Mol Hepatol. 2025;31(1):304-307.

Transcriptomic signature in advanced hepatocellular carcinoma tissue to predict combination immunotherapy response: Editorial on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”

Hiroaki Kanzaki, Yujin Hoshida

Clin Mol Hepatol. 2025;31(1):308-310.

Personalized approaches to the treatment of hepatocellular carcinoma using immune checkpoint inhibitors: Editorial on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”

Naoshi Nishida

Clin Mol Hepatol. 2025;31(1):311-315.

The urgent need for multidisciplinary approaches in managing alcohol-associated liver disease: Editorial on “The prognostic impact of psychiatric intervention on alcohol-associated liver disease: The UK Biobank cohort study”

Soon Sun Kim, Jae Youn Cheong

Clin Mol Hepatol. 2025;31(1):316-318.

Understanding the impact on digestive disease in the post-COVID-19 condition: Editorial on “Long-term gastrointestinal and hepatobiliary outcomes of COVID-19: A multinational population-based cohort study from South Korea, Japan, and the UK”

Yang-Hyun Baek

Clin Mol Hepatol. 2025;31(1):319-322.

Stroma-tology: Predicting recurrence in cholangiocarcinoma: Editorial on “Development and validation of a stromal-immune signature to predict prognosis in intrahepatic cholangiocarcinoma”

Sergi Marco, Chiara Braconi

Clin Mol Hepatol. 2025;31(1):323-326.

Snapshot Metabolic dysfunction-associated steatotic liver disease across women’s reproductive lifespan and issues

Clara Meda, Arianna Dolce, Sara Della Torre

Clin Mol Hepatol. 2025;31(1):327-332.

Letters to the Editor Accountability in AI medicine: A critical appraisal of ChatGPT in patient self-management and screening

Jiawen Wang, Tian Xia

Clin Mol Hepatol. 2025;31(1):e1-e2.

Comparison of the therapeutic effects of transarterial radioembolization and tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis

Hang Li, Hua Lu, Xi-Ping Shen, Xiao-Song Li

Clin Mol Hepatol. 2025;31(1):e3-e4.

Contemporary awareness of viral hepatitis between 2012 and 2022 among Korean adults

Donghee Kim, Won Kim, Aijaz Ahmed

Clin Mol Hepatol. 2025;31(1):e5-e7.

Insights on risk score development: Considerations for early-stage hepatocellular carcinoma models

Zhanna Zhang, Gongqiang Wu

Clin Mol Hepatol. 2025;31(1):e8-e9.

Grading severity of microvascular invasion in hepatocellular carcinoma: More details, more significance

Xiu-Ping Zhang, Fei-Fan Wu, Tian-Chen Zhang, Zhen-Qi Li, Ming-Gen Hu, Rong Liu

Clin Mol Hepatol. 2025;31(1):e10-e12.

Letter to the editor on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”

Meng-Che Wu, Hui-Chin Chang, Yi-Sheng Jhang, Shuo-Yan Gau

Clin Mol Hepatol. 2025;31(1):e13-e14.

Letter to the editor on “Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis”

Xiao-Song Li, Xi-Ping Shen, Hang Li

Clin Mol Hepatol. 2025;31(1):e15-e16.

Development of risk scores for prognosis prediction among patients with early-stage hepatocellular carcinoma

Xiping Shen, Ji Wu

Clin Mol Hepatol. 2025;31(1):e17-e18.

Chronic hepatitis B, extrahepatic malignancies and the use of antiviral drugs

Meng-Che Wu, Shih-Chi Yang, Shuo-Yan Gau

Clin Mol Hepatol. 2025;31(1):e19-e20.

Letter regarding “Prevalence of clinically significant liver fibrosis in the general population”

Wei Feng, Qile Wang, Qingwang Ye

Clin Mol Hepatol. 2025;31(1):e21-e22.

Comment: Non-invasive prediction of post-sustained virological response hepatocellular carcinoma in hepatitis C virus

Xinpu Miao, Haidong Wu, Jinrong Xu, Wei Cheng

Clin Mol Hepatol. 2025;31(1):e23-e24.

The fibrosis-4 index for advanced liver fibrosis in NAFLD with T2DM: Half a loaf is better than no bread

Zeyu Wang, Dong Wan, Meidong Xu, Yong Jiang

Clin Mol Hepatol. 2025;31(1):e25-e26.

Presence of liver fibrosis in chronic hepatitis B patients with varying serum hepatitis B virus DNA levels: Letter to the editor on “Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B”

Jian Wang, Shaoqiu Zhang, Chuanwu Zhu, Yuanwang Qiu, Chao Wu, Rui Huang

Clin Mol Hepatol. 2025;31(1):e27-e30.

Comprehensive analysis of transcriptomic biomarkers for predicting response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma

Binghua Li, Jingyuan Wen, Zhu Xu, Peng Yan, Bing Han, Decai Yu

Clin Mol Hepatol. 2025;31(1):e31-e34.

Sex-specific associations of metabolic dysfunction-associated steatotic liver disease with cardiovascular outcomes

Meng-Yuan Miao, Jie-Qiong Lyu, Wei Jiang, Zhong-Yue Liu, Guo-Chong Chen

Clin Mol Hepatol. 2025;31(1):e35-e38.

Urgent need for education on hepatocellular carcinoma surveillance among high-risk population in China

Lei Cai, Chao Li, Li-Yang Sun, Yong-Kang Diao, Ming-Da Wang, Tian Yang

Clin Mol Hepatol. 2025;31(1):e39-e43.

Correspondences Correspondence to editorial on “Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting”

Shunda Du, Karin Wisskirchen, Ke Zhang, Ulrike Protzer

Clin Mol Hepatol. 2025;31(1):e44-e47.

Correspondence to editorial on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis”

Hee Yeon Kim, Miyoung Choi, Dae Won Jun

Clin Mol Hepatol. 2025;31(1):e48-e51.

Correspondence to editorial on “Optimal cutoffs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis”

Jung Hwan Yu, Seung Up Kim

Clin Mol Hepatol. 2025;31(1):e52-e54.

Correspondence to editorial on “Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis”

Young-Joo Jin, Seung Up Kim

Clin Mol Hepatol. 2025;31(1):e55-e57.

Correspondence to editorial on “UBE2S promotes glycolysis in hepatocellular carcinoma by enhancing E3 enzyme-independent polyubiquitination of VHL”

Renyu Zhang, Ding Wei, Zhinan Chen, Huijie Bian

Clin Mol Hepatol. 2025;31(1):e58-e60.

Correspondence to editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis”

Young Eun Chon, Jung Hwan Yu, Seung Up Kim

Clin Mol Hepatol. 2025;31(1):e61-e63.

Steatotic liver disease in chronic hepatitis C related hepatocellular carcinoma: Inflictor or bystander?: Correspondence to editorial on “Dynamic change of metabolic dysfunction-associated steatotic liver disease in chronic hepatitis C patients after viral eradication: A nationwide registry study in Taiwan”

Chung-Feng Huang, Ming-Lun Yeh, Chia-Yen Dai, Jee-Fu Huang, Wan-Long Chuang, Ming-Lung Yu

Clin Mol Hepatol. 2025;31(1):e64-e66.

PNPLA3 is one of the bridges between TM6SF2 E167K variant and MASLD: Correspondence to editorial on “TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD”

Baokai Sun, Likun Zhuang

Clin Mol Hepatol. 2025;31(1):e67-e69.

Correspondence to editorial on “DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dysfunction-associated steatotic liver disease”

Amal Magdy, Hee-Jin Kim, Won Kim, Mirang Kim

Clin Mol Hepatol. 2025;31(1):e70-e73.

Correspondence to editorial on: “Gut microbiome and metabolome signatures in liver cirrhosis-related complications”

Satya Priya Sharma, Ki Tae Suk

Clin Mol Hepatol. 2025;31(1):e74-e77.

Correspondence to editorial on “KCTD17-mediated Ras stabilization promotes hepatocellular carcinoma progression”

Sang Bae Lee, KyeongJin Kim

Clin Mol Hepatol. 2025;31(1):e78-e80.

Correspondence to editorial 1 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 Trial”

Sung Hwan Lee, Sun Young Yim, Ji Hoon Kim, Sunyoung S. Lee, Ahmed O. Kaseb, Ju-Seog Lee

Clin Mol Hepatol. 2025;31(1):e81-e83.

Correspondence to editorial 2 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 trial”

Sun Young Yim, Sung Hwan Lee, Ji Hoon Kim, Sunyoung S Lee, Ahmed O Kaseb, Ju-Seog Lee

Clin Mol Hepatol. 2025;31(1):e84-e86.

Correspondence to editorial on “Long-term gastrointestinal and hepatobiliary outcomes of COVID-19: a multinational population-based cohort study from South Korea, Japan, and the UK”

Kwanjoo Lee, Jaeyu Park, Jinseok Lee, Hayeon Lee, Yeonjung Ha, Dong Keon Yon

Clin Mol Hepatol. 2025;31(1):e87-e89.

Correspondence to editorial on “Development and validation of a stromal-immune signature to predict prognosis in intrahepatic cholangiocarcinoma”

Yu-Hang Ye, Shao-Lai Zhou

Clin Mol Hepatol. 2025;31(1):e90-e92.

Correspondence to letter to the editor on “Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis”

Moon Haeng Hur, Yoon Jun Kim

Clin Mol Hepatol. 2025;31(1):e93-e95.

Correspondence to letter to the editor 1 on “Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma”

Chun-Ting Ho, Elise Chia-Hui Tan, Chien-Wei Su

Clin Mol Hepatol. 2025;31(1):e96-e97.

Correspondence to letter to the editor on “Sorafenib vs. lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: a real-world study”

Young Eun Chon, Dong Yun Kim, Hong Jae Chon, Do Young Kim

Clin Mol Hepatol. 2025;31(1):e98-e100.

Correspondence to letter to the editor 2 on “Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma”

Chun-Ting Ho, Elise Chia-Hui Tan, Chien-Wei Su

Clin Mol Hepatol. 2025;31(1):e101-e102.

Correspondence to letter to the editor on “Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis”

Yuri Cho, Dae Won Jun

Clin Mol Hepatol. 2025;31(1):e103-e104.

Correspondence to letter to the editor on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis”

Hee Yeon Kim, Miyoung Choi, Dae Won Jun

Clin Mol Hepatol. 2025;31(1):e105-e107.

Correspondence to letter to the editor on “Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B”

Gi-Ae Kim, Seung Won Choi, Young-Suk Lim

Clin Mol Hepatol. 2025;31(1):e108-e109.

Correspondence to letter to the editor on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”

Sung Hwan Lee, Sun Young Yim, Ji Hoon Kim, Sunyoung S Lee, Ahmed O Kaseb, Peng Wei, Ju-Seog Lee

Clin Mol Hepatol. 2025;31(1):e110-e112.

Replys to Correspondence Reply to correspondence on “Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting”

Antonio Bertoletti, Anthony T Tan

Clin Mol Hepatol. 2025;31(1):e113-e116.

Reply to correspondence on “Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis”

Mirko Zoncapè, Emmanuel A. Tsochatzis

Clin Mol Hepatol. 2025;31(1):e117-e118.

Reply to correspondence on “UBE2S: A novel driver of HIF-1alpha-induced metabolic reprogramming in hepatocellular carcinoma”

Martina Mang Leng Lei, Terence Kin Wah Lee

Clin Mol Hepatol. 2025;31(1):e119-e120.

Reply to correspondence on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”

Hiroaki Kanzaki, Yujin Hoshida

Clin Mol Hepatol. 2025;31(1):e121-e122.

Reply to correspondence on “Long-term gastrointestinal and hepatobiliary outcomes of COVID-19: A multinational population-based cohort study from South Korea, Japan, and the UK”

Yang-Hyun Baek

Clin Mol Hepatol. 2025;31(1):e123-e124.